E.HuberA
Limitations of the Current Evidence Any honest treatment of this topic has to foreground its own limitations, because the strength of the conclusions is bounded by the weakness of the underlying data
Thus proper administration of GSH as an antimicrobial agent (either in the form of aerosol inhalation, spray, wound care gel, coatings on medical implants/equipment, oral therapy) will add a significantly to the ability to quickly treat the wide variety of P

Addressing this gap, this review offers three integrated contributions: first, it positions ferroptosis as a convergent metabolic executioner across a broader spectrum of kidney diseasesencompassing AKI, DN, renal interstitial fibrosis, systemic lupus erythematosus (SLE) nephritis, autosomal dominant polycystic kidney disease (ADPKD), renal cell carcinoma (RCC), and contrast-induced nephropathy (CIN)while emphasizing cell type-specific vulnerabilities: tubular epithelial cells (susceptible via mitochondrial dysfunction), podocytes (via iron overload), and immune cells (e.g., neutrophils/macrophages in SLE nephritis) exhibit context-dependent ferroptosis regulation, governed by cell type-specific modulators [e.g., Nrf2 in tubules, heme oxygenase-1 (HO-1) in macrophages, and sirtuins in podocytes]
Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells